|
1
|
Ouyang DJ, Chen QT, Anwar M, Xie N, Ouyang QC, Fan PZ, Qian LY, Chen GN, Zhou EX, Guo L, Gu XW, Ding BN, Yang XH, Liu LP, Deng C, Xiao Z, Li J, Wang YQ, Zeng S, Wang S, Yi W. The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study. Front Pharmacol 2021; 12:682568. [PMID: 34512325 PMCID: PMC8428978 DOI: 10.3389/fphar.2021.682568] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 07/26/2021] [Indexed: 12/12/2022] Open
Abstract
Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. Methods: Ninety-four patients who received pyrotinib as a third- or higher-line treatment for HER2-positive MBC were included in this retrospective study. The primary and secondary endpoints were overall survival (OS) and progression‐free survival (PFS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were implemented to balance important patient characteristics between groups. Results: Thirty (31.9%) patients were pretreated with lapatinib and subsequently received pyrotinib as an anti-HER2 treatment, and 64 (68.1%) patients did not receive this treatment. The OS and PFS indicated a beneficial trend in lapatinib-naive group compared to lapatinib-treated group in either the original cohort (PFS: 9.02 vs 6.36 months, p = 0.05; OS: 20.73 vs 14.35 months, p = 0.08) or the PSM (PFS: 9.02 vs 6.08 months, p = 0.07; OS: 19.07 vs 18.00 months, p = 0.61) or IPTW (PFS: 9.90 vs 6.17 months, p = 0.05; OS: 19.53 vs 15.10 months, p = 0.08) cohorts. Subgroup analyses demonstrated lapatinib treatment-related differences in PFS in the premenopausal subgroup and the no prior trastuzumab treatment subgroup, but no significant differences were observed in OS. Conclusion: Pyrotinib-based therapy demonstrated promising effects in HER2-positive MBC patients in a real-world study, especially in lapatinib-naive patients, and also some activity in lapatinib-treated patients.
Collapse
Affiliation(s)
- D J Ouyang
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.,Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China
| | - Q T Chen
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
| | - M Anwar
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
| | - N Xie
- Department of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - Q C Ouyang
- Department of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - P Z Fan
- Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China
| | - L Y Qian
- Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China
| | - G N Chen
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
| | - E X Zhou
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
| | - L Guo
- Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
| | - X W Gu
- Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China
| | - B N Ding
- Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China
| | - X H Yang
- Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - L P Liu
- Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - C Deng
- Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Z Xiao
- Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
| | - J Li
- Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - Y Q Wang
- Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - S Zeng
- Department of Internal Medicine-Oncology, Xiangya Hospital, Central South University, Changsha, China
| | - Shouman Wang
- Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
| | - Wenjun Yi
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
| |
Collapse
|
|
2
|
Liu D, Wang J, Xiao Q, Tian XC, Zhu CR, Jiang JX, Wang CM, Xu Q, Gu XW, Hu HM. [Ossifying fibromyxoid tumor: clinicolpathological futures of 3 cases]. Zhonghua Bing Li Xue Za Zhi 2020; 49:174-176. [PMID: 32074732 DOI: 10.3760/cma.j.issn.0529-5807.2020.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D Liu
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - J Wang
- Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Q Xiao
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - X C Tian
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - C R Zhu
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - J X Jiang
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - C M Wang
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - Q Xu
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - X W Gu
- Department of Pathology, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
| | - H M Hu
- Department of Pathology, Xiangcheng People's Hospital of Jiangsu Province, Suzhou 215131, China
| |
Collapse
|
|
3
|
Xiao Q, Chen J, Liu D, Wang CM, Xu Q, Gu XW. [Clinicopathological features of succinate dehydrogenase-deficient renal cell carcinoma]. Zhonghua Bing Li Xue Za Zhi 2019; 48:796-798. [PMID: 31594045 DOI: 10.3760/cma.j.issn.0529-5807.2019.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Q Xiao
- Department of Pathology, Northern Jiangsu People's Hospital, Jiangsu Province, Yangzhou 225001, China
| | - J Chen
- Department of Pathology, the People's Hospital of Jingjiang City, Jiangsu Province, Taizhou 214500, China
| | - D Liu
- Department of Pathology, Northern Jiangsu People's Hospital, Jiangsu Province, Yangzhou 225001, China
| | - C M Wang
- Department of Pathology, Northern Jiangsu People's Hospital, Jiangsu Province, Yangzhou 225001, China
| | - Q Xu
- Department of Pathology, Northern Jiangsu People's Hospital, Jiangsu Province, Yangzhou 225001, China
| | - X W Gu
- Department of Pathology, Northern Jiangsu People's Hospital, Jiangsu Province, Yangzhou 225001, China
| |
Collapse
|
|
4
|
Xiao Q, Liu D, Zhu CR, Wang CM, Xu Q, Gu XW, Wu HT. [Clinicopathological features of eosinophilic solid and cystic renal cell carcinoma]. Zhonghua Bing Li Xue Za Zhi 2019; 48:715-717. [PMID: 31495093 DOI: 10.3760/cma.j.issn.0529-5807.2019.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Q Xiao
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - D Liu
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - C R Zhu
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - C M Wang
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - Q Xu
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - X W Gu
- Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| | - H T Wu
- Department of Medical Imaging, Northern Jiangsu People's Hospital, Yangzhou 225001, China
| |
Collapse
|